Early treatment is associated with better short- and long-term outcomes.
Faciobrachial dystonic seizures (FBDS) are a prominent clinical manifestation of leucine-rich glioma-inactivated 1 (LGI1) limbic encephalitis that responds to immunosuppressants (NEJM JW Neurol Mar 2017 and Neurology 2016; 87:1449). The current investigators characterized 103 patients who presented with FBDS due to LGI1 encephalitis, assessing the effect of treatment on disease course and cognitive outcomes.
Median age was 64 (range, 22–92). Those identified after the description of this entity in 2011 had received earlier immunotherapy (median, 45 days after onset) compared with those diagnosed before 2011 (median, 112 days). Cognitive impairment was present in 33% of the pre-2011 cohort but only 7% of the post-2011 cohort. Those with cogni…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)